Phase 1 Trial Recruiting: Bispecific Antibodies JNJ-87189401 and JNJ-78278343
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxXaluritamig (AMG 509): Promising Updates on a STEAP1-Targeted Therapy for Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 1 trial: AVA6000 Targeted Chemotherapy for FAP-Positive Tumors (Including Prostate Cancer)
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 trial of QXL138AM: A Targeted Therapy for Prostate Cancer and Other CD138-Expressing Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 trial of INV-9956: A Promising CYP11A1 Inhibitor Targeting Drug-Resistant Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Enrolling: Novel Copper-61 Radiotracer Shows Promise in Prostate Cancer Precision Imaging
/0 Comments/in Clinical Trial, Localized, Metastatic, Non-Metastatic, Phase 1, Phase 1/by MaxPhase I Trial for Novel Cancer Drug: VVD-130850
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 3 Clinical Trial for Xaluritamig (AMG 509) in Advanced Prostate Cancer Set to Open for Recruitment Soon
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxInvikafusp Alfa: New Hope for Advanced, Anti-PD-1 Resistant Cancers Phase 1 and 2 Trial
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxTags
abiraterone acetate ADC ADT alphafold androgen deprivation therapy antibody-drug conjugate apalutamide artificial intelligence ATM bispecific antibody BRCA cancer immunotherapy cancer treatment castration-resistant prostate cancer chemotherapy clinical trial clinical trials crispr darolutamide docetaxel drug discovery drug repurposing drug resistance enzalutamide hormone therapy immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer metformin mHSPC neuroendocrine prostate cancer oncology oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals STAMPEDE trial STAT3 STEAP1 T-cell therapy theranostics treatment resistance
Latest Posts
- Update on CLS-1025: Precision T Cell Engager Phase 1 Study Expected in Early 2025 January 17, 2025
- UMass Scientists Develop Novel Bacteria-Based Cancer Therapy January 16, 2025
- Harnessing PROTAC Technology: A Novel Approach to Targeting ERG in Prostate Cancer January 15, 2025
- VIR-5500: A Promising T-Cell Engager for Advanced Prostate Cancer January 14, 2025